ANI Pharmaceuticals, Inc. $ANIP Shares Acquired by First Trust Advisors LP

First Trust Advisors LP grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 12.8% during the 1st quarter, Holdings Channel reports. The fund owned 99,747 shares of the specialty pharmaceutical company’s stock after purchasing an additional 11,346 shares during the period. First Trust Advisors LP’s holdings in ANI Pharmaceuticals were worth $7,671,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ANIP. Maryland State Retirement & Pension System raised its holdings in shares of ANI Pharmaceuticals by 5.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after purchasing an additional 134 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after purchasing an additional 198 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in ANI Pharmaceuticals by 5.1% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after purchasing an additional 200 shares during the last quarter. Federation des caisses Desjardins du Quebec boosted its holdings in ANI Pharmaceuticals by 0.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock valued at $3,110,000 after purchasing an additional 221 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its position in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 249 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $79.24 on Friday. The company has a market capitalization of $1.80 billion, a PE ratio of 20.06 and a beta of 0.43. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The company’s fifty day moving average price is $81.13 and its 200 day moving average price is $79.52. ANI Pharmaceuticals, Inc. has a 1 year low of $62.60 and a 1 year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Analyst Ratings Changes

ANIP has been the subject of a number of recent research reports. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Guggenheim reaffirmed a “buy” rating and set a $124.00 target price on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Canaccord Genuity Group began coverage on ANI Pharmaceuticals in a research report on Thursday, July 16th. They set a “hold” rating and a $91.00 price target for the company. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $105.00.

Insider Activity

In related news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $81.84, for a total value of $40,920.00. Following the completion of the transaction, the vice president owned 77,390 shares of the company’s stock, valued at approximately $6,333,597.60. This represents a 0.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.36, for a total value of $231,876.00. Following the transaction, the chief financial officer owned 174,693 shares in the company, valued at $14,213,022.48. This represents a 1.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 88,029 shares of company stock worth $6,954,472. 8.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.